The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Aug 21 (Reuters) - Gilead Sciences' (GILD.O), opens new tab unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance ...

Santa Monica-based Kite, a Gilead company, agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. “In vivo therapy is ...

Gilead Sciences' cell therapy unit Kite has reached an agreement to buy Interius BioTherapeutics, bolstering its efforts to develop therapies that do not require cells to be removed from the body ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Gilead subsidiary Kite Pharma said Thursday ...

The cell and gene therapy field is experiencing a renaissance of sorts, with about a dozen products approved in the past few years. However, most of these therapies require physicians to collect and ...

PHILADELPHIA, May 18, 2021 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Philadelphia company is ...

Will initiate a first-in-human Phase 1 clinical trial for INT2104, its first-in-class in vivo targeted gene therapy, creating CAR cells for the treatment of B cell malignancies in 4Q24 PHILADELPHIA, ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the best growth stocks to buy for the next 2 years. On August 22, Gilead Sciences, through its subsidiary Kite, announced its acquisition of Interius ...